Cargando…
Cost of three models of care for drug-resistant tuberculosis patients in Nigeria
BACKGROUND: Nigeria accounts for a significant proportion of the global drug-resistant tuberculosis (DR-TB) burden, a large proportion of which goes untreated. Different models for managing DR-TB treatment with varying levels of hospitalization are in use across Nigeria, however costing evidence is...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327521/ https://www.ncbi.nlm.nih.gov/pubmed/30630429 http://dx.doi.org/10.1186/s12879-018-3636-1 |
_version_ | 1783386484676493312 |
---|---|
author | Bada, Florence O. Okpokoro, Evaezi Blok, Nick Meribole, Emmanuel Dutt, Saswata Dakum, Patrick Abimiku, Alash’le Zwerling, Alice Kik, Sandra V. |
author_facet | Bada, Florence O. Okpokoro, Evaezi Blok, Nick Meribole, Emmanuel Dutt, Saswata Dakum, Patrick Abimiku, Alash’le Zwerling, Alice Kik, Sandra V. |
author_sort | Bada, Florence O. |
collection | PubMed |
description | BACKGROUND: Nigeria accounts for a significant proportion of the global drug-resistant tuberculosis (DR-TB) burden, a large proportion of which goes untreated. Different models for managing DR-TB treatment with varying levels of hospitalization are in use across Nigeria, however costing evidence is required to guide the scale up of DR-TB care. We aimed to estimate and compare the costs of different DR-TB treatment and care models in Nigeria. METHODS: We estimated the costs associated with three models of DR-TB treatment and care: Model (A) patients are hospitalized throughout the 8-month intensive phase, Model (B) patients are partially hospitalized during the intensive phase and Model (C) is entirely ambulatory. Costs of treatment, in-patient and outpatient care and diagnostic and monitoring tests were collected using a standardized data collection sheet from six sites through an ingredient’s approach and cost models were based on the Nigerian National Tuberculosis, Leprosy and Buruli Ulcer Guideline - Sixth Edition (2014) and Guideline for programmatic and clinical management of drug-resistant tuberculosis in Nigeria (2015). RESULTS: Assuming adherence to the Nigerian DR-TB guidelines, the per patient cost of Model A was $18,528 USD, Model B $15,159 USD and Model C $9425 USD. Major drivers of cost included hospitalization (Models A and B) and costs of out-patient consultations and supervision (Model C). CONCLUSION: Utilizing a decentralized ambulatory model, is a more economically viable approach for the expansion of DR-TB care in Nigeria, given that patient beds for DR-TB treatment and care are limited and costs of hospitalized treatment are considerably more expensive than ambulatory models. Scale-up of less expensive ambulatory care models should be carefully considered in particular, when treatment efficacy is demonstrated to be similar across the different models to allow for patients not requiring hospitalization to be cared for in the least expensive way. |
format | Online Article Text |
id | pubmed-6327521 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-63275212019-01-15 Cost of three models of care for drug-resistant tuberculosis patients in Nigeria Bada, Florence O. Okpokoro, Evaezi Blok, Nick Meribole, Emmanuel Dutt, Saswata Dakum, Patrick Abimiku, Alash’le Zwerling, Alice Kik, Sandra V. BMC Infect Dis Research Article BACKGROUND: Nigeria accounts for a significant proportion of the global drug-resistant tuberculosis (DR-TB) burden, a large proportion of which goes untreated. Different models for managing DR-TB treatment with varying levels of hospitalization are in use across Nigeria, however costing evidence is required to guide the scale up of DR-TB care. We aimed to estimate and compare the costs of different DR-TB treatment and care models in Nigeria. METHODS: We estimated the costs associated with three models of DR-TB treatment and care: Model (A) patients are hospitalized throughout the 8-month intensive phase, Model (B) patients are partially hospitalized during the intensive phase and Model (C) is entirely ambulatory. Costs of treatment, in-patient and outpatient care and diagnostic and monitoring tests were collected using a standardized data collection sheet from six sites through an ingredient’s approach and cost models were based on the Nigerian National Tuberculosis, Leprosy and Buruli Ulcer Guideline - Sixth Edition (2014) and Guideline for programmatic and clinical management of drug-resistant tuberculosis in Nigeria (2015). RESULTS: Assuming adherence to the Nigerian DR-TB guidelines, the per patient cost of Model A was $18,528 USD, Model B $15,159 USD and Model C $9425 USD. Major drivers of cost included hospitalization (Models A and B) and costs of out-patient consultations and supervision (Model C). CONCLUSION: Utilizing a decentralized ambulatory model, is a more economically viable approach for the expansion of DR-TB care in Nigeria, given that patient beds for DR-TB treatment and care are limited and costs of hospitalized treatment are considerably more expensive than ambulatory models. Scale-up of less expensive ambulatory care models should be carefully considered in particular, when treatment efficacy is demonstrated to be similar across the different models to allow for patients not requiring hospitalization to be cared for in the least expensive way. BioMed Central 2019-01-10 /pmc/articles/PMC6327521/ /pubmed/30630429 http://dx.doi.org/10.1186/s12879-018-3636-1 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Bada, Florence O. Okpokoro, Evaezi Blok, Nick Meribole, Emmanuel Dutt, Saswata Dakum, Patrick Abimiku, Alash’le Zwerling, Alice Kik, Sandra V. Cost of three models of care for drug-resistant tuberculosis patients in Nigeria |
title | Cost of three models of care for drug-resistant tuberculosis patients in Nigeria |
title_full | Cost of three models of care for drug-resistant tuberculosis patients in Nigeria |
title_fullStr | Cost of three models of care for drug-resistant tuberculosis patients in Nigeria |
title_full_unstemmed | Cost of three models of care for drug-resistant tuberculosis patients in Nigeria |
title_short | Cost of three models of care for drug-resistant tuberculosis patients in Nigeria |
title_sort | cost of three models of care for drug-resistant tuberculosis patients in nigeria |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327521/ https://www.ncbi.nlm.nih.gov/pubmed/30630429 http://dx.doi.org/10.1186/s12879-018-3636-1 |
work_keys_str_mv | AT badaflorenceo costofthreemodelsofcarefordrugresistanttuberculosispatientsinnigeria AT okpokoroevaezi costofthreemodelsofcarefordrugresistanttuberculosispatientsinnigeria AT bloknick costofthreemodelsofcarefordrugresistanttuberculosispatientsinnigeria AT meriboleemmanuel costofthreemodelsofcarefordrugresistanttuberculosispatientsinnigeria AT duttsaswata costofthreemodelsofcarefordrugresistanttuberculosispatientsinnigeria AT dakumpatrick costofthreemodelsofcarefordrugresistanttuberculosispatientsinnigeria AT abimikualashle costofthreemodelsofcarefordrugresistanttuberculosispatientsinnigeria AT zwerlingalice costofthreemodelsofcarefordrugresistanttuberculosispatientsinnigeria AT kiksandrav costofthreemodelsofcarefordrugresistanttuberculosispatientsinnigeria |